Polypodium Leucotomos Extract: Science-Backed Uses & Dosage

Author: Reviewed by Dr. Reviewed by Dr. Amanda Oakley, Dermatologist, Hamilton, New Zealand. Source: Adapted from high-quality dermatologic research. Synonyms: Polypodium leucotomos, fern extract, anapsos, Helicidys polypodioides.

What is polypodium leucotomos?

Polypodium leucotomos is a tropical fern native to Central and South America, particularly Honduras and Panama. Its extract, derived from the leaves, has been utilized in traditional medicine for centuries to treat inflammatory skin conditions such as psoriasis and atopic dermatitis. The standardized extract, often referred to as anapsos, contains bioactive compounds including polyphenols, flavonoids, and alkaloids that confer potent antioxidant and anti-inflammatory properties.

Modern clinical research has validated its efficacy in dermatology, primarily for photoprotection against ultraviolet (UV), visible, and infrared radiation. The extract works by scavenging free radicals, inhibiting matrix metalloproteinases (MMPs), preserving collagen and elastin, and modulating inflammatory pathways. These mechanisms reduce oxidative stress, DNA damage, and inflammation induced by solar exposure.

Available as oral supplements (typically 240–480 mg tablets or capsules) or topical formulations, polypodium leucotomos extract (PLE) is generally well-tolerated with minimal side effects. Doses range from 480 mg daily for photoprotection to higher amounts (up to 960 mg) for therapeutic uses in pigmentary disorders.

What is polypodium leucotomos extract used for?

PLE is primarily employed for its broad-spectrum photoprotective effects and as an adjunct therapy in various dermatoses. Key applications include:

• Acute chemophotoprotection: Taken before sun exposure to minimize sunburn, DNA damage, and immunosuppression.
• Photoageing and skin cancer prevention: Reduces photoaging signs and risk of photocarcinogenesis.
• Polymorphic light eruption (PMLE): Decreases eruption frequency and severity.
• Solar urticaria: Provides symptomatic relief in photosensitive urticaria.
• Vitiligo: Enhances repigmentation when combined with phototherapy.
• Melasma: Improves hyperpigmentation as monotherapy or adjunct.
• Other uses: Atopic dermatitis, post-inflammatory hyperpigmentation (PIH), actinic keratosis (AK), and high-risk melanoma patients.

Acute chemophotoprotection

PLE offers systemic photoprotection when ingested 2–3 hours prior to UV exposure. Clinical trials demonstrate that 480 mg doses increase the minimal erythema dose (MED) by 2.3–3 fold for UVB and 2.7–4 fold for UVA. This translates to reduced sunburn cells, apoptotic keratinocytes, and p53 expression in irradiated skin.

In a randomized controlled trial, participants taking 7.5 mg/kg PLE twice daily for 2 months before PUVA therapy showed 2.44 times higher UVA tolerance doses compared to placebo. Immunohistochemistry revealed decreased cyclobutane pyrimidine dimers (CPDs) and Langerhans cell depletion, indicating preserved immunosurveillance.

For practical use, adults take 240–480 mg orally 30–60 minutes before sun exposure, repeatable up to twice daily. It complements topical sunscreens, extending protection across UV, visible, and infrared spectra.

Photoageing and skin cancer

Chronic sun exposure accelerates photoaging via ROS-induced MMP activation, ECM degradation, and angiogenesis. PLE counters this by boosting glutathione (GSH) levels, inhibiting NF-κB and AP-1, and reducing MMP-1, COX-2, and VEGF expression.

Human studies show oral PLE (480 mg twice daily for 60 days) reduces UV-induced erythema, hyperpigmentation, and immediate pigment darkening. Long-term use diminishes solar elastosis and atypical keratinocytes, potentially lowering non-melanoma skin cancer (NMSC) risk. In high-risk melanoma patients, PLE adjunctively enhances antioxidant capacity and reduces UV immunosuppression.

Post-photodynamic therapy (PDT) for AK, PLE accelerates lesion clearance by 25–50% via anti-inflammatory effects.

Polymorphic light eruption

PMLE affects 10–20% of populations in temperate climates, triggered by UVA. Three placebo-controlled trials confirm PLE (480 mg twice daily starting 15 days pre-exposure) reduces PMLE incidence by 85–90% and severity scores by 70%.

Mechanism involves Th2 polarization (↑IL-10, TGF-β), mast cell stabilization, and WBC infiltration blockade. Ideal for outdoor workers or recreational sun exposure where topical measures fail.

Solar urticaria

In open-label studies, PLE (1–2 tablets daily) raised urticaria thresholds, reducing wheal formation and pruritus in visible/UVA-induced cases. It inhibits mast cell degranulation and histamine release via anti-inflammatory modulation.

Vitiligo

As adjunct to PUVA or NB-UVB, PLE (7.5 mg/kg twice daily) accelerates repigmentation. A double-blind trial reported 44% marked improvement vs. 11% placebo after 3 months. Facial lesions respond fastest (13 sessions), extremities slower (22 sessions). Children and darker skin types fare better, with sustained results up to 2 years.

PLE preserves melanocytes by reducing ROS, enhancing DNA repair, and promoting S-phase arrest for repair.

Melasma

A randomized trial of 240 mg twice daily for 12 weeks reduced Melasma Area Severity Index (MASI) from 5.7 to 3.3 (p<0.05) vs. placebo worsening. 60% achieved mild-marked improvement photographically.

Benefits stem from antioxidant protection against UV-induced melanogenesis and MMP inhibition preserving dermal integrity.

Other uses

• Atopic dermatitis: 360–480 mg daily reduces inflammation, itching in children.
• PIH: Theoretical via COX-2 inhibition and cytokine modulation.
• Photodermatoses: Adjuvant for lupus, porphyria.
• Psoriasis: Anti-proliferative effects warrant further study.

Mechanism of action

PLE’s pleiotropic effects include:

• Antioxidant: ↑GSH/GSSG ratio, scavenges ROS, protects mtDNA.
• Anti-inflammatory: ↓TNF-α, NO, iNOS, COX-2, PGE2; modulates NF-κB, AP-1.
• Immunomodulatory: ↑Langerhans cells, Th2 shift.
• Anti-carcinogenic: ↓p53 mutants, sunburn cells, angiogenesis.

Dosage

• Photoprotection: 240–480 mg 2–3h pre-exposure, max 960 mg/day.
• Chronic: 480 mg BID for 2–3 months.
• Pediatric: Weight-based, e.g., 7.5 mg/kg.

Side effects and contraindications

Excellent safety profile; rare mild GI upset. Contraindicated in hypersensitivity. Pregnancy category B; limited data.

Frequently asked questions

Q: How does PLE protect against sun damage?

A: By antioxidant action, DNA repair enhancement, and inflammation blockade across UV/VIS/IR spectra.

Q: Is PLE safe for long-term use?

A: Yes, studies up to 6 months show no serious adverse effects.

Q: Can PLE replace sunscreen?

A: No, it complements topical SPF for systemic protection.

Q: Best dose for vitiligo?

A: 7.5 mg/kg twice daily with phototherapy.

Q: Does it help children?

A: Yes, effective and safe in pediatric atopic dermatitis and vitiligo.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb